Alain Katic
Child & Adolescent Psychiatry · Bellaire, TXNPI 1871605741
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $80,760 of the $105,818 with a category attached, or 76.3%. Supernus Pharmaceuticals, Inc. accounts for 78.2% of it on its own, with 23 other manufacturers making up the rest. Among child & adolescent psychiatry clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 965 payments — averaging $109.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$83K
- Ironshore Pharmaceuticals Inc.$6K
- Tris Pharma Inc$5K
- Corium, LLC$3K
- Bausch Health US, LLC$1K
- Neos Therapeutics, LP$1K
- plus $6K from 18 others
Across 304 payments — averaging $5281.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$390K
- Supernus Pharmaceuticals, Inc.$323K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$301K
- Corium, LLC$190K
- Boehringer Ingelheim International GmbH$107K
- Arbor Pharmaceuticals, Inc.$96K
- plus $197K from 8 others
What the payments were for
- Consulting fees$1,5001%
- Speaking & faculty fees$80,76076%
- Travel & lodging$5,9326%
- Food & beverage$17,60517%
- Education$220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 181 | $82,758 |
| Ironshore Pharmaceuticals Inc. | 96 | $6,033 |
| Tris Pharma Inc | 70 | $4,943 |
| Corium, LLC | 115 | $3,318 |
| Bausch Health US, LLC | 75 | $1,270 |
| Neos Therapeutics, LP | 66 | $1,061 |
| Otsuka America Pharmaceutical, Inc. | 52 | $1,038 |
| Takeda Pharmaceuticals U.S.A., Inc. | 53 | $929 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 36 | $713 |
| AbbVie(2 entities) | 50 | $711 |
| Sunovion Pharmaceuticals Inc. | 23 | $430 |
| Johnson & Johnson | 16 | $409 |
| Eisai Inc. | 20 | $390 |
| Lundbeck LLC | 18 | $350 |
| Adlon Therapeutics L.p. | 14 | $276 |
| Noven Therapeutics, LLC | 23 | $262 |
| Collegium Pharmaceutical, Inc. | 10 | $183 |
| Rhodes Pharmaceuticals L.p. | 12 | $173 |
| Shire North American Group Inc | 14 | $173 |
| Axsome Therapeutics, Inc. | 7 | $154 |
| Arbor Pharmaceuticals, Inc. | 7 | $114 |
| Vertical Pharmaceuticals, LLC | 5 | $94 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$72,117
- Jornay PM 20mg capsules (Bottle of 100)$4,251
- Dyanavel XR$3,728
- Quillivant$3,604
- Quillichew ER$3,604
- Azstarys$1,700
- Adzenys XR-ODT$117
- Cotempla XR-ODT$117
- SPRAVATO$111
How this compares
$105,818 in reported general payments places this provider in the 95th percentile of 301 child & adolescent psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrintellixVortioxetine Hydrobromide | 20 | $9,376 |
| Lisdexamfetamine Dimesylate | 31 | $6,795 |
| CymbaltaDuloxetine Hcl | 12 | $6,775 |
| VyvanseLisdexamfetamine Dimesylate | 16 | $5,972 |
| MydayisDextroamphetamine/Amphetamine | 12 | $4,095 |
| Dextroamphetamine Sulfate | 28 | $3,132 |
| Bupropion XlBupropion Hcl | 104 | $2,013 |
| Methylphenidate ErMethylphenidate Hcl | 15 | $1,997 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 74 | $1,916 |
| Clozapine | 13 | $1,504 |
| Zolpidem Tartrate | 48 | $1,372 |
| Clonazepam | 63 | $1,045 |
| Alprazolam | 97 | $977 |
| Aripiprazole | 30 | $917 |
| Duloxetine Hcl | 37 | $819 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $929 | $15,34836 claims |
| Shire North American Group IncMydayis | $173 | $4,09512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 301 child & adolescent psychiatry providers in Texas.
Other child & adolescent psychiatry in Bellaire
- Steven PliszkaSan Antonio$59K
- Mary Garcia HolguinSan Antonio$24K
- John SteffekSpring$14K
- Robert MosquedaEdinburg$13K
- Gloria BrunGreenville$10K
- Mudassar TariqSugar Land$9K
- Charles PryzantDallas$9K
- Mehvesh AfrinaPlano$8K
- Kishore SunkaraHurst$8K
- Moses RamosDesoto$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.